Good morning :)
$
₹
Aptevo Therapeutics Inc

Aptevo Therapeutics Inc

APVO

NASDAQ
Asset Logo

Aptevo Therapeutics Inc

APVO

NASDAQ
$1.49—% (+1.49)
$
₹
$1.49—% (+1.49)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Unknown

Sector and industry information not available

Micro Cap

With a market cap of $9.8M the stock is ranked 5718

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

0.00
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

0.73
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$7,758.2
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Based on 1 analyst's reports

Buy
1 analyst
Hold
0 analyst
Sell
0 analyst

Price Upside

+5394.18%

Earnings Growth

—

Rev. Growth

—

Company Profile

Company Profile

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
19.90
19.90
1Y Return
40.01%
40.01%
Buy Reco %
67.85
67.85
Compare with Peers

Financials

Financials

Income

Balance Sheet

Cash Flow

Hmm, looks like data is currently unavailable. Once it's updated, you can view it here

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Aptevo Therapeutics Inc 0.000.730
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare APVO with any stock or ETF
Compare APVO with any stock or ETF
Comparing from
APVO
ABBV
AMGN
Loading...

Frequently asked questions

  1. Aptevo Therapeutics Inc (APVO) share price today is $1.49 as of October 27, 2026 at 12:11 AM IST. The stock touched a day high of $1.73 and a day low of $1.45.

  2. Aptevo Therapeutics Inc stock trades on NASDAQ under the ticker symbol APVO.

  3. Aptevo Therapeutics Inc's market capitalization is $9.83M as of October 27, 2026 at 12:11 AM IST.

  4. Aptevo Therapeutics Inc's price-to-earnings (P/E) ratio is 0.00 as of October 26, 2026.

  5. Aptevo Therapeutics Inc's price-to-book (P/B) ratio is 0.73 as of October 26, 2026.

  6. Yes, You can buy Aptevo Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Aptevo Therapeutics Inc shares in three steps: 1. Search Aptevo Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Aptevo Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Aptevo Therapeutics Inc (APVO) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 6.6889 shares at the current price of $1.49.

Loading...